Indigo Naturalis in Inflammatory Bowel Disease: mechanisms of action and insights from clinical trials
- PMID: 38948310
- PMCID: PMC11194518
- DOI: 10.3831/KPI.2024.27.2.59
Indigo Naturalis in Inflammatory Bowel Disease: mechanisms of action and insights from clinical trials
Abstract
This study investigates the therapeutic potential of Indigo Naturalis (IN) in treating a Inflammatory Bowel Disease (IBD). The objective is to comprehensively examine the effects and pharmacological mechanisms of IN on IBD, assessing its potential as an novel treatment for IBD. Analysis of 11 selected papers is conducted to understand the effects of IN, focusing on compounds like indirubin, isatin, indigo, and tryptanthrin. This study evaluates their impact on Disease Activity Index (DAI) score, colon length, mucosal damage, and macrophage infiltration in Dextran Sulfate Sodium (DSS)-induced colitis mice. Additionally, It investigate into the anti-inflammatory mechanisms, including Aryl hydrocarbon Receptor (AhR) pathway activation, Nuclear Factor kappa B (NF-κB)/nod-like receptor family pyrin domain containing 3 (NLRP3)/Interleukin 1 beta (IL-1β) inhibition, and modulation of Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MYD88)/NF-κB and Mitogen Activated Protein Kinase (MAPK) pathways. Immunomodulatory effects on T helper 17 (Th17)/regulatory T cell (Treg cell) balance and Glycogen synthase kinase-3 beta (GSK3-β) expression are also explored. Furthermore, the study addresses the role of IN in restoring intestinal microbiota diversity, reducing pathogenic bacteria, and increasing beneficial bacteria. The findings reveal that IN, particularly indirubin and indigo, demonstrates significant improvements in DAI score, colon length, mucosal damage, and macrophage infiltration in DSS-induced colitis mice. The anti-inflammatory effects are attributed to the activation of the AhR pathway, inhibition of inflammatory pathways, and modulation of immune responses. These results exhibit the potential of IN in IBD treatment. Notably, the restoration of intestinal microbiota diversity and balance further supports its efficacy. IN emerges as a promising and effective treatment for IBD, demonstrating anti-inflammatory effects and positive outcomes in preclinical studies. However, potential side effects necessitate further investigation for safe therapeutic development. The study underscores the need for future research to explore a broader range of active ingredients in IN to enhance therapeutic efficacy and safety.
Keywords: Indigo Naturalis; anti-inflammatory; immunomodulation; inflammatory bowel disease; intestinal microbiota; random clinical trial.
© 2024 Korean Pharmacopuncture Institute.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare no conflicts of interest in this work.
Similar articles
-
Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota.Front Pharmacol. 2021 Jul 22;12:674416. doi: 10.3389/fphar.2021.674416. eCollection 2021. Front Pharmacol. 2021. PMID: 34366843 Free PMC article.
-
Glycyrrhiza uralensis Fisch. alleviates dextran sulfate sodium-induced colitis in mice through inhibiting of NF-κB signaling pathways and modulating intestinal microbiota.J Ethnopharmacol. 2022 Nov 15;298:115640. doi: 10.1016/j.jep.2022.115640. Epub 2022 Aug 24. J Ethnopharmacol. 2022. PMID: 36030029
-
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.Autophagy. 2020 Jan;16(1):38-51. doi: 10.1080/15548627.2019.1635384. Epub 2019 Jul 9. Autophagy. 2020. PMID: 31286804 Free PMC article. Review.
-
Indigo Naturalis Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice by Modulating the Intestinal Microbiota Community.Molecules. 2019 Nov 12;24(22):4086. doi: 10.3390/molecules24224086. Molecules. 2019. PMID: 31726738 Free PMC article.
-
Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.Immunol Invest. 2023 Apr;52(3):364-397. doi: 10.1080/08820139.2023.2168554. Epub 2023 Feb 6. Immunol Invest. 2023. PMID: 36745138 Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources